FOXO4-DRI is a synthetic 46-amino-acid SENOLYTIC peptide, designed to selectively kill senescent ('zombie') cells that accumulate with age and drive inflammation, while sparing healthy cells.
FOXO4-DRI Prices
24 vendors · 11 with an issuer-verified COA · lowest 10mg from $60.00 · checked
Where to buy FOXO4-DRI: 24 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| $60.00 | Buy FOXO4-DRI from Ascension Peptides | |
| 6-test panelVerified COAFreedom Diagnostics · Tested Sep 27, 2026 | $89.96 | Buy FOXO4-DRI from MS Peptides |
| 3-test panelVerified COAFreedom Diagnostics | $90.00 | Buy FOXO4-DRI from Novaglo Research |
| 3-test panelCOA on fileMarfleet Analytical Services | $98.2210mg packageChecked today | Buy FOXO4-DRI from Pure Peptides UK |
| $100.45 | Buy FOXO4-DRI from Atlas Longevity | |
| 6-test panelVerified COAKovera Labs · Tested Feb 16, 2026 | $121.49 | Buy FOXO4-DRI from Glacier Aminos |
| $123.74 | Buy FOXO4-DRI from Swift Peptides | |
| 6-test panelVerified COABioSyn Systems · Tested Apr 1, 2026 | $134.39 | Buy FOXO4-DRI from Cenexa Labs |
| 2-test panelVerified COAJanoshik · Tested Jul 14, 2026 | $134.99 | Buy FOXO4-DRI from ZestyRat Research |
| 4-test panelVerified COAKovera Labs · Tested Aug 12, 2026 | $144.0010mg packageChecked today | Buy FOXO4-DRI from Real Peptides |
| $149.25 | Buy FOXO4-DRI from Atomik Labz | |
| 4-test panelVerified COABioViridian | $161.99 | Buy FOXO4-DRI from Glow Peptides |
| 3-test panelVerified COAFreedom Diagnostics · Tested Sep 2, 2026 | $161.99 | Buy FOXO4-DRI from Rebirth Labs |
| $169.0010mg packageChecked today | Buy FOXO4-DRI from Particle Peptides | |
| $178.20 | Buy FOXO4-DRI from Dynotides | |
| 5-test panelCOA on fileAverix Laboratories (in-house) · Tested Jul 16, 2026 | $179.99 | Buy FOXO4-DRI from Averix Labs |
| 3-test panelVerified COAVanguard Laboratory · Tested Aug 1, 2026 | $179.99 | Buy FOXO4-DRI from Peptide Giants |
| $191.24 | Buy FOXO4-DRI from SomaChems | |
| 2-test panelVerified COAOptima Labs | $194.9910mg packageChecked Oct 6 | Buy FOXO4-DRI from Peptides Lab UK |
| $195.30 | Buy FOXO4-DRI from Nationwide Peptides | |
| $227.5810mg packageChecked today | Buy FOXO4-DRI from Kensington Labs | |
| 2-test panelVerified COAJanoshik · Tested Apr 17, 2026 | $242.25 | Buy FOXO4-DRI from Paramount Peptides |
| $247.47 | Buy FOXO4-DRI from BioLongevity Labs | |
| $289.9910mg packageChecked today | Buy FOXO4-DRI from Legion Peptides |
Tracked every day
FOXO4-DRI listing prices, tracked daily
The five cheapest in-stock package prices for FOXO4-DRI on each collected day, and the vendors that most often held those places.
Five cheapest in-stock package prices per day
Listed package price before coupons, any vial size. This is not the coupon-adjusted lowest 10mg price used to rank the comparison.
- Cheapest$65.99
- 2nd cheapest$98.22
- 3rd cheapest$99.95
- 4th cheapest$100.00
- 5th cheapest$111.61
Vendors most often in the cheapest five
- Swift Peptides24 days$65.990.0%
- MS Peptides19 days$99.95-16.7%
- Pure Peptides UK17 days$98.220.0%
- Ascension Peptides17 days$120.00last seen Oct 7, 2026-9.8%
- Glacier Aminos17 days$134.99last seen Oct 6, 2026+25.0%
- Novaglo Research3 days$100.000.0%
- Atlas Longevity2 days$111.61-0.3%
- Offline Peptides1 day$69.00last seen Sep 25, 20260.0%
Current market data
FOXO4-DRI Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for FOXO4-DRI is $60.00 from Ascension Peptides. The median across vendors is $161.99.
- Lowest 10mg cost
- $60.00Ascension Peptides
- Median 10mg cost
- $161.99One normalized offer per vendor
- Lowest package total
- $49.49Swift Peptides · package size may differ
- Public COA coverage
- 100%24 of 24 vendors
What the market shows
PeptidePrices found 25 in-stock listings from 24 vendors, checked through Oct 9, 2026. The lowest 10mg cost is 63% below the vendor median of $161.99; 11 vendors (46%) fall below that median. 24 of 24 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is FOXO4-DRI? Research, safety, and status
FOXO4-DRI is one of the most mechanistically distinctive peptides in research: a senolytic, meaning its goal is to selectively eliminate senescent cells rather than to signal growth, repair, or metabolism like most peptides here. Senescent cells are damaged cells that stop dividing but don't die, accumulating with age and secreting inflammatory SASP factors that degrade surrounding tissue. FOXO4-DRI is designed to clear them.
First described by Peter de Keizer's group at Erasmus University Medical Center in 2017, it restored fur density, kidney function, and physical fitness in aged mice and protected against chemotherapy toxicity. Crucially, all of that is preclinical, there are no human trials. It is not FDA-approved, and everything below is research context, not medical guidance.
Key research takeaways
It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive: p53 is freed to relocate to mitochondria and trigger apoptosis. A reported ~11.7-fold selectivity for senescent over healthy cells is its signature finding.
It uses a D-Retro-Inverso design (reversed sequence built from D-amino acids), which resists protease breakdown while preserving the binding shape, plus a cell-penetrating tail to get inside cells.
All evidence is preclinical, mouse and cell studies (de Keizer lab, Cell 2017). There are ZERO human trials, and a theoretical p53/tumor-suppressor concern is the key open question. Not FDA-approved.
FOXO4-DRI at a glance
PeptidePrices safety rating
3/10 · Not FDA-approved
Mechanism
D-amino acid retro-inverso FOXO4 peptide; disrupts FOXO4-p53 interaction in senescent cells; triggers selective apoptosis of senescent cells (senolytic); clears 'zombie cells' without harming normal cells.
Research areas
Senolytic therapy (clearing senescent cells); anti-aging / longevity; age-related dysfunction; fibrosis; chronic inflammation; cancer research.
Regulatory / research status
Research / preclinical only
Half-life
~2-4 hours. D-amino acid backbone resists proteolysis, extending activity.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Potential weight loss, lethargy in animal models. Long-term human data very limited. Theoretical risk: removal of beneficial senescent cells in wound healing.
Experimental senolytic that works by disrupting the FOXO4-p53 interaction. p53 is the master tumor-suppressor protein, modulating it carries serious theoretical oncogenic risk, and there is zero human safety data. Animal data only. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- FOXO4-DRI is a D-amino acid retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells; in normal senescent cells FOXO4 sequesters p53 in nuclear PML bodies, preventing its pro-apoptotic function, FOXO4-DRI competitively displaces this interaction, causing p53 nuclear exclusion and activation of apoptosis selectively in senescent cells.
- The landmark 2017 Cell paper demonstrated that FOXO4-DRI restored fitness, fur density, and renal function in both fast-aging XpdTTD/TTD mice and naturally aged mice, and reduced doxorubicin-induced chemotoxicity in a senescence-dependent manner, providing the first in vivo proof that selective senescent cell elimination with a peptide reverses multiple aging-associated phenotypes.
- Subsequent studies validated FOXO4-DRI's senolytic activity across tissue types: it reduces senescent Leydig cells in aged testes to restore testosterone synthesis, improves spermatogenesis, and induces apoptosis in senescent keloid fibroblasts via p53-serine15 nuclear exclusion, demonstrating broad applicability across diverse senescent cell populations.
- Unlike small-molecule senolytics (navitoclax, dasatinib), FOXO4-DRI's selectivity arises from FOXO4's specific over-expression in senescent rather than quiescent cells; this differential expression creates a therapeutic window, though the peptide's in vivo delivery, immunogenicity in humans, and optimal dosing schedule remain active areas of investigation.
Selected references
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell, 2017
- Rejuvenation by Therapeutic Elimination of Senescent Cells · Cell, 2017
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice · Aging (Albany NY), 2020
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation · Commun Biol, 2025
- FOXO4-DRI improves spermatogenesis in aged mice through reducing SASP secretion from Leydig cells · Exp Gerontol, 2024
- Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis · JCI Insight, 2021
Related pages